期刊文献+

全血细胞减少的鉴别诊断 被引量:3

下载PDF
导出
摘要 全血细胞减少临床上也称为全血象减少或者三系减少,指红细胞数量或血红蛋白含量、白细胞数量及血小板数量低于正常。即RBC<3.0×1012/L,HB<110g/L,WBC<4.0×109/L(中性粒细胞<2.0×109/L),PLT<100×109/L,是一种特殊的疾病状态。全血细胞减少是一组高度异质性疾病在某一侧面的共同表现,而非一独立疾病。它主要见于造血系统疾病,但非造血系统疾病引起的全血细胞减少并非少见,常被忽略,易引起误诊,全血细胞减少症可分为骨髓生产障碍(包括骨髓增生减低及骨髓无效造血)及外周消耗过多两大类。来自造血组织以外的其他脏器非恶性肿瘤性疾病,包括肝脏、肾脏、结缔组织、类脂质储存病以及内分泌疾病等都可以引起血液学改变[1-2]。
出处 《西藏医药》 2017年第6期84-85,共2页 Tibetan Medicine
  • 相关文献

参考文献3

二级参考文献19

  • 1Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibro- sis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) IJ]. Leuk Res, 2007, 31 (6):737- 740.
  • 2Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs ~ J ]. J Clin Oncol, 2012, 30(33):4098-4103.
  • 3Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity [J]. Haematologica, 2005, 90(8):1128-1132.
  • 4Tefferi A, Vardiman JW. Classification and diagnosis of myelo- proliferative neoplasms: the 2008 World Health Organization cri- teria and point-of-care diagnostic algorithms [J]. Leukemia, 2008, 22 ( 1 ): 14-22.
  • 5Tefferi A, Thiele J, Vannuechi AM, et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diag- nostic eriteria for myeloproliferative neoplasms [Jl. Leukemia, 2014, 28(7):1407-1413.
  • 6Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the Inter- national Working Group for Myelofibrosis Research and Treat- ment[J]. Blood, 2009, 113( 13): 2895-2901.
  • 7Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) IJ~. Blood, 2010, 115(9):1703-1708.
  • 8Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status I J]. J Clin Oncol, 2011, 29(4):392-397.
  • 9Xu Z, Gale RP, Zhang Y, et al. Unique features of primary myelofibrosis in Chinese I J ]. Blood, 2012, 119 ( 11 ) :2469-2473.
  • 10Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia~J~. Br J Haematol, 1999, 104(4):730-737.

共引文献259

同被引文献30

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部